I
Ingrid M. Meszoely
Researcher at Vanderbilt University Medical Center
Publications - 80
Citations - 4314
Ingrid M. Meszoely is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 29, co-authored 71 publications receiving 3783 citations. Previous affiliations of Ingrid M. Meszoely include Fox Chase Cancer Center & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis
Yoshiharu Miyamoto,Anirban Maitra,Bidyut Ghosh,Ulrich Zechner,Pedram Argani,Christine A. Iacobuzio-Donahue,Virote Sriuranpong,Tatsuya Iso,Ingrid M. Meszoely,Michael S. Wolfe,Ralph H. Hruban,Douglas W. Ball,Roland M. Schmid,Steven D. Leach +13 more
TL;DR: It is suggested that Notch mediates the tumor-initiating effects of TG alpha by expanding a population of undifferentiated precursor cells.
Journal ArticleDOI
Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates
Anna L. Means,Ingrid M. Meszoely,Kazufumi Suzuki,Yoshiharu Miyamoto,Anil K. Rustgi,Robert J. Coffey,Christopher V.E. Wright,Doris A. Stoffers,Steven D. Leach +8 more
TL;DR: It is shown that pancreatic epithelial explants undergo spontaneous acinar-to-ductal metaplasia in response to EGFR signaling, and that this change in epithelial character is associated with the appearance of nestin-positive transitional cells.
Journal ArticleDOI
Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results
Thomas E. Yankeelov,Martin Lepage,Martin Lepage,Anuradha Bapsi Chakravarthy,Elizabeth E. Broome,Kenneth J. Niermann,Mark C. Kelley,Ingrid M. Meszoely,Ingrid A. Mayer,Cheryl R. Herman,Kevin McManus,Ronald R. Price,John C. Gore +12 more
TL;DR: The analysis presented here is sensitive to longitudinal changes in breast tumor status; K(trans) and ADC are most sensitive to these changes.
Journal ArticleDOI
Nonoperative management of primary colorectal cancer in patients with stage IV disease.
Charles R. Scoggins,Ingrid M. Meszoely,Charles D. Blanke,R. Daniel Beauchamp,Steven D. Leach +4 more
TL;DR: In this article, the authors postulated that resection of primary colorectal tumors could be avoided safely in a select population of asymptomatic colon cancer patients presenting with incurable stage IV disease.
Journal ArticleDOI
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
Justin M. Balko,Rebecca S. Cook,David B. Vaught,Maria G. Kuba,Todd W. Miller,Neil E. Bhola,Melinda E. Sanders,N. M. Granja-Ingram,J. Joshua Smith,Ingrid M. Meszoely,Janine Salter,Mitch Dowsett,Katherine Stemke-Hale,Ana M. Gonzalez-Angulo,Gordon B. Mills,Joseph A. Pinto,Henry L. Gomez,Carlos L. Arteaga +17 more
TL;DR: DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy, and inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment inBLBC xenografts.